Abstract
Introduction: Negative symptoms, neurocognitive deficits, and functional impairment are prevalent in individuals with major depressive disorder (MDD) and schizophrenia (SCZ). However, unlike neurocognitive deficits, little is known about the role of negative symptoms toward functioning in individuals with MDD. This study aimed to examine the contributions of negative symptoms and neurocognitive impairments in functioning in individuals with MDD, compared to individuals with SCZ.
Methods: Participants included 50 individuals with MDD, 49 individuals with SCZ, and 49 healthy controls. Measures administered included the Negative Symptom Assessment (NSA-16), Brief Assessment of Cognition in Schizophrenia (BACS), Patient Health Questionnaire (PHQ-9), and MIRECC-Global Assessment of Functioning (MIRECC-GAF).
Results: Both MDD and SCZ groups had significantly more severe negative symptoms and poorer functioning than healthy controls. Individuals with SCZ performed significantly poorer on the BACS than the other two groups. Motivation was significantly correlated with occupational functioning in MDD, while both negative symptoms and neurocognition correlated with social and occupational functioning in SCZ.
Conclusion: Negative symptoms and neurocognitive deficits play differential roles in functioning between MDD and SCZ. Future longitudinal studies are needed to better understand these associations.
Introduction
For decades, researchers have recognized that both MDD and Schizophrenia cause significant "functional impairment"—difficulty maintaining jobs or social relationships. In Schizophrenia, two major culprits are well-established: neurocognitive deficits (memory and attention) and negative symptoms (loss of motivation, social withdrawal).
In MDD, the focus has traditionally been on "positive" depressive symptoms like sadness. While cognitive hurdles are known in MDD, the role of negative symptoms is poorly understood. This paper seeks to bridge that gap by comparing how these factors influence real-world functioning across both disorders.
Methods
The researchers conducted a cross-sectional study in Singapore, recruiting 148 participants: 50 with MDD, 49 with SCZ, and 49 healthy controls (HC). All participants were screened using the Structured Clinical Interview for DSM-IV (SCID). The clinical battery included the NSA-16 for negative symptoms, BACS for neurocognition, PHQ-9 for depressive severity, and MIRECC-GAF to evaluate occupational, social, and symptom-related functioning.
Key Results and Insights
Negative Symptoms are Universal
Surprisingly, the MDD and SCZ groups showed similar levels of total negative symptoms. This challenges the traditional view that negative symptoms are a hallmark exclusive to Schizophrenia. Both patient groups had significantly lower functioning scores across all domains compared to controls ($p < 0.001$).
Cognitive "Shielding" in MDD
The MDD group performed significantly better on cognitive tests than the SCZ group and was comparable to healthy controls. The SCZ group performed significantly worse on the BACS composite score ($M = -1.60$) compared to the MDD group ($M = 0.13$) and Healthy Controls ($M = -0.17$). This might be due to the MDD participants being relatively young (average age ~36) with a shorter duration of illness.
Differential Impact on Functioning
The study found that the drivers of functional impairment differ by diagnosis:
- In MDD: The "motivation" subdomain was the only negative symptom significantly tied to occupational functioning ($r = -0.48, p < 0.001$). General depressive symptoms (PHQ-9) drove social and overall impairment, but amotivation specifically targeted the workplace.
- In Schizophrenia: Almost all factors, including cognition and various negative symptom domains, correlated with poor functioning.
Discussion and Conclusion
Negative symptoms and neurocognitive deficits appear to play differential roles in individual domains of functioning between MDD and SCZ. In MDD, lack of motivation is a primary driver of work-related impairment, whereas in Schizophrenia, both cognitive deficits and a broader range of negative symptoms collectively hinder social and occupational functioning.
Limitations include the cross-sectional design, which prevents establishing causality, and the use of the NSA-16, which was originally designed for Schizophrenia. Future longitudinal studies with larger samples are necessary to track how these symptoms evolve and whether cognitive deficits become a more prominent functional barrier in MDD as patients age.
Summary updated